We market medicines that are designed to improve the health and quality of life of patients in the UK - medicines which are innovative and effective.
The content on this page is intended for members of the public unless otherwise stated.
Cardiovascular and Metabolic diseases
Byetta® (exenatide) - for Healthcare Professionals Only
Bydureon® (exenatide) - for Healthcare Professionals Only
Crestor® (rosuvastatin) - for Healthcare Professionals Only
Forxiga® (dapagliflozin) - for Healthcare Professionals Only
Onglyza® (saxagliptin) - for Healthcare Professionals Only
Infection and Vaccines
Duaklir® Genuair (aclidinium/formoterol) - for Healthcare Professionals Only
Eklira® Genuair (aclidinium/bromide) - for Healthcare Professionals Only
Report an adverse event
All pharmacologically effective drugs have benefits and risks. The risk may be insignificant or may be acceptable in relation to the drug's therapeutic action. Continuous monitoring of the safety of a drug throughout the duration of its use helps to ensure that its risks and benefits remain acceptable. AstraZeneca is committed to protecting the safety of patients who receive our products. All adverse events should be reported to AstraZeneca by freephone +44 (0) 1582 836836.
Atlas ID: 997028.011
Date of Preparation: August 2016